A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
Status:
Withdrawn
Trial end date:
2020-06-09
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, multi-stage, phase II trial of Trifluridine/tipiracil as a
palliative treatment for patients with metastatic triple negative breast cancer who have
failed both a taxane and anthracycline or have contraindications to these agents.